Indaptus Therapeutics is trading 10.86% down at $1.15 after continued profit-taking following its 46.81% surge on August 20 and 6.52% decline on August 21.
- No fresh company-specific announcement was identified for August 24; the latest corporate update was second-quarter results released August 13.
- Broader risk-off sentiment is adding pressure, with the Nasdaq Composite down 0.64% amid Iran sanctions threats, failed U.S.-Canada trade talks, elevated Treasury yields, and upcoming Nvidia earnings and Jackson Hole events.